Backed by €400 million (US$449 million) in EU-cleared German aid, the new Frankfurt facility is designed to secure insulin supply for people with diabetes from 2032.
News|Podcasts|September 15, 2026
Simtra BioPharma Solutions’ Bloomington Capacity Expansions
Author(s)Simtra
In this exclusive podcast, Bo Watkins (SVP, Sales & Business Management) and Pat Adams (VP, Expansion Operations) of Simtra BioPharma Solutions discuss the company's major manufacturing expansion in Bloomington, Indiana. The conversation covers the new Building H facility and the Park Campus development, and how these investments are designed to expand US sterile injectable and high-potency manufacturing capacity. They also detail the practical benefits for customers, the digital capabilities supporting the buildout, and what the expansion means for Simtra's Bloomington workforce and community.
KEY TAKEAWAYS
- Learn how Building H and the Park Campus work together to expand Simtra's sterile injectable and high-potency manufacturing capacity in Bloomington, Indiana.
- Understand how Simtra is positioning its new facilities to close a capacity gap in commercial-scale manufacturing for ADCs and bioconjugates.
- Discover how Simtra's investment in digital factory capabilities and resilient facility design supports greater transparency and reliability for customers.
Related to this article
At AAPS PharmSci 360, Thermo Fisher Scientific scientists described how predictive modeling guides technology selection for poorly soluble drugs, and outlined plans to bring solvent-free KinetiSol technology to commercial scale in 2027.
Zylidac will test whether optogenetic cell lines that hit 21 g/L in small-scale CHO runs can deliver higher-yield complex biologics at GMP scale.
Risvutatug rezetecan extended median progression-free survival to 5.5 months vs 1.4 months with chemotherapy in pretreated osteosarcoma.
Izalontamab brengitecan extended median progression-free survival to 11.1 months vs 5.7 months with chemotherapy after EGFR TKI failure.
Revakinagene taroretcel (Encelto), the only FDA-approved MacTel therapy, slowed photoreceptor loss by up to 54.8% vs sham in phase 3 trials.
Rohit Tripathi, vice president of industry strategy, consumer packaged goods, and manufacturing at RELEX Solutions, explains what is driving biopharma reshoring, how USMCA uncertainty complicates sourcing for biologics, and where cold-chain visibility still breaks down.
EA2251, the 7th registrational trial of ivonescimab, will test it plus chemotherapy vs pembrolizumab or durvalumab regimens in first-line BTC.
Trending on BioPharm International
1
Adalvo Acquires Enzene’s Romiplostim Biosimilar Program for ITP
2
Merck and Kelun’s Sac-TMT Extends Survival by Nearly 7 Months in Pretreated Endometrial Cancer
3
Aclaris’ TSLP/IL-4Rα Bispecific ATI-052 Shows Early Activity in Atopic Dermatitis and Asthma
4
The BioPharm Brief: Survival Gains, a Modest ADC Win, and CAR-T in Multiple Sclerosis
5